The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lupin Investments Pvt Ltd Lupin - Disclosure Of Related Party Transactions For The Half-YearEnded March 31, 2022.ĭisclosure of Related Party Transactions for the half-yearended March 31, 2022. Lupin Diagnostics Launches its First Regional Reference Laboratory in Patna.ĭisclosure pursuant to loss of share certificate by the shareholder(s). Lupin Limited has informed the Exchange about press release dated 1 titled Lupin Diagnostics Launches its First Regional Reference Laboratory in Patna. Intimation regarding loss of share certificate by the shareholder. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding Annual General Meeting of Lupin Limited on August 3, 2022. Lupin - Shareholders Meeting / AGM On August 3, 2022. Lupin - Corporate Action-Board to consider Dividendĭisclosure under Regulations 42 and 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the Record date for the purpose of ascertaining the shareholders entitled to payment of dividend if declared at the Annual General Meeting of the Company to be held on August 3, 2022. Lupin's Somerset Manufacturing Plant Receives EIR from US FDA. Lupin view the company background of various companies, including their addresses, telephone numbers, fax numbers, industry and the details of their. Lupin - Announcement under Regulation 30 (LODR)-Press Release / Media Release PhonePe Beat of Progress Powered by Moneycontrol Unlocking opportunities in Metal and Mining Prabhudas Lilladher recommended accumulate rating on Lupin with a target price of Rs 950 in its research report February 07, 2022.Mcmarketstockprice->Moneycontrol/MC_Market/MC_Market_StockPrice_728x90|~|Moneycontrol/MC_Market/MC_Market_StockPrice_300x250|~|Moneycontrol/MC_Market/MC_Market_StockPrice_728x90_2|~|Moneycontrol/MC_Market/MC_Market_StockPrice_728x90_1|~|Moneycontrol/MC_Market/MC_Market_StockPrice_300x250_2|~|Moneycontrol/MC_Market/MC_Market_StockPrice_300x250_1|~|Moneycontrol/MC_Market/MC_Market_StockPrice_300x250_BTF|~|Moneycontrol/MC_PriceChart/MC_PriceChart_300x250_ATF|~|Moneycontrol/MC_PriceChart/MC_PriceChart_728x90_ATF|~|Moneycontrol/MC_PriceChart/MC_PriceChart_728x90_BTF|~|Moneycontrol/MC_Market/MC_Market_StockPrice_300x250/MC_Market_StockPrice_Notices_300x250_ATF|~|Moneycontrol/MC_Market/MC_Market_StockPrice_QuartResult_728x90|~|Moneycontrol/MC_Market/MC_Market_StockPrice_CapitalStruc_728x90|~|Moneycontrol/MC_Market/MC_Market_StockPrice_PriceChart_728x90|~|Moneycontrol/MC_Market/MC_Market_StockPrice_History_300圆00_ATF|~|Moneycontrol/MC_PriceChart/MC_PriceChart_300x250_ATF_1|~|Moneycontrol/MC_PriceChart/MC_PriceChart_728x90_ATF_1|~|Moneycontrol/MC_PriceChart/MC_PriceChart_300x250_MTF->
The US Food and Drug Administration (USFDA) has approved the company's sNDA to expand the use of Solosec in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and above, Lupin Ltd said in a regulatory filing.
The company has received approval from the United States Food and Drug Administration (FDA) to market the generic version of Bausch Health Americas’ Jublia topical solution, the Mumbai-based drug maker said in a regulatory filing.
#Lupin moneycontrol series
Interview Series Business In The Week Ahead.